Hims Hair (Finasteride + Minoxidil)vsMusely Hair Formula Rx

Hims Hair targets male-pattern baldness two ways at once. Finasteride blocks the enzyme 5-alpha-reductase, which converts testosterone into DHT, the hormone that shrinks genetically susceptible scalp follicles; lowering scalp DHT slows that miniaturization. Minoxidil works on a different pathway, widening blood vessels and prolonging the follicle's active growth (anagen) phase to reactivate dormant follicles and thicken existing hairs. Used together as a daily scalp spray, they aim to slow loss (finasteride) while stimulating regrowth (minoxidil).

Musely Hair Formula Rx is a custom prescription that a compounding pharmacy makes after a telehealth provider reviews your photos and medical history. The topical "Hair Solution" (Classic) typically blends minoxidil 8% (widens scalp blood vessels and extends the follicle's growth phase), dutasteride (blocks both types of 5-alpha-reductase, the enzyme that creates DHT, the hormone that miniaturizes follicles in pattern hair loss), spironolactone (an additional anti-androgen), tretinoin (intended to boost minoxidil penetration), and ketoconazole plus hydrocortisone (to calm scalp inflammation and irritation). A "Modern" topical adds ingredients such as latanoprost, caffeine, and melatonin. The oral "Hair Pill" pairs low-dose oral minoxidil with dutasteride to suppress DHT systemically, and women's formulas may include spironolactone. The goal is to attack hair loss through multiple pathways at once. Note that Musely's topical uses dutasteride rather than finasteride; both block DHT, but dutasteride is more potent and has a much longer half-life.

The active ingredients are individually well-validated. In the pivotal oral finasteride 1mg trials cited on the Propecia FDA label, 48% of men had increased hair count at 12 months versus 7% on placebo; in 5-year data, 48% showed increased growth, 42% had no further loss, and about 10% continued losing. For topical minoxidil, a 393-man, 48-week randomized trial found 5% minoxidil produced roughly 45% more regrowth than 2% minoxidil by target-area hair counts. Combining a 5-alpha-reductase inhibitor with minoxidil generally outperforms either alone. Important caveat: Hims' specific compounded 0.3% topical finasteride / 6% minoxidil spray has not been studied in large dedicated FDA trials, so its exact regrowth numbers are inferred from the individual drugs, not proven for this product.

The core actives are well-supported, though Musely's specific compounded formula has not been tested in its own published controlled trial, so efficacy is inferred from its ingredients rather than the branded product. Topical minoxidil is the only FDA-approved topical for androgenetic alopecia (oral finasteride and oral minoxidil's relatives aside, minoxidil is the topical standard): in the pivotal Olsen 2002 randomized trial of 393 men, 5% topical minoxidil produced a mean increase of about 18.6 non-vellus hairs/cm2 versus about 3.9 with placebo at 48 weeks, with roughly 60% of users rated improved on global photographic assessment versus about 23% on placebo. A 2025 systematic review and meta-analysis of 7 randomized trials (N=396) found topical minoxidil-finasteride combinations beat minoxidil alone, with a mean difference of about 9 more hairs/cm2 in density and significantly better global photographic assessment. A separate small 2025 RCT (N=40) found topical 0.1% finasteride plus 5% minoxidil performed about the same as minoxidil alone over a short 12-week window, a reminder that the added DHT-blocker benefit can take longer to show and that Musely's stronger dutasteride-based formula has not been individually validated.

Local effects are most common: scalp itching, dryness, flaking, redness, or irritation from the alcohol/minoxidil base, plus possible unwanted facial hair if the product migrates. Minoxidil can cause a temporary early shed in the first weeks. Finasteride's known risks include decreased libido, erectile dysfunction, and ejaculation disorders (roughly 1-2% in oral trials, modestly above placebo). Serious or rarer concerns on the FDA finasteride label include depression, suicidal ideation, gynecomastia, and sexual side effects that can persist after stopping (sometimes called post-finasteride syndrome). Critically, in April 2025 the FDA alerted clinicians and consumers about compounded topical finasteride after reports of erectile dysfunction, anxiety, suicidal ideation, brain fog, depression, fatigue, insomnia, decreased libido, and testicular pain, many of which continued after discontinuation; topical use lowers but does not eliminate systemic absorption. Minoxidil can rarely cause dizziness or rapid heartbeat. Stop and seek care for chest pain, swelling, fainting, or mood changes.

Common local effects from the topical include scalp itching, dryness, flaking, redness, stinging, and a temporary increase in shedding in the first 4-12 weeks. Minoxidil can cause unwanted facial hair if it migrates and, rarely, dizziness, fluid retention, or palpitations. The serious concern is the DHT blocker: in April 2025 the FDA issued a safety alert after receiving 32 reports (2019-2024) of systemic adverse events from compounded topical finasteride, including decreased libido, erectile dysfunction, depression, anxiety, suicidal ideation, brain fog, fatigue, and insomnia, some of which persisted after stopping. Musely's topical uses dutasteride rather than finasteride, but dutasteride is a more potent, longer-acting 5-alpha-reductase inhibitor and is also absorbed through the skin, so the same class of systemic risks reasonably applies and has not been ruled out. Spironolactone can cause menstrual changes, breast tenderness, and elevated potassium. Stop and seek medical care for mood changes, suicidal thoughts, chest pain, or breathing problems.

As of 2026, the Hims topical finasteride + minoxidil spray starts around $35/month, with the lowest per-month price when billed and shipped on a longer (for example, multi-month) cycle. For comparison, Hims oral finasteride runs about $22/month and standalone minoxidil about $15/month. There may also be a low-cost or one-time medical consultation fee. These are cash-pay telehealth/compounded products, so insurance typically does not cover them; generic oral finasteride filled at a pharmacy with a prescription can sometimes be cheaper (often around $10-25/month with discount cards) for those who do not need the topical convenience.

As of 2026, Musely hair treatments are out-of-pocket; insurance generally does not cover compounded cosmetic-hair prescriptions, though FSA/HSA cards may be accepted. Expect roughly $95-$155 for a multi-month (about three-month) supply depending on the formula and whether you choose auto-refill (cheaper, advertised at up to ~30% off) or a one-time purchase, plus a one-time ~$20 doctor-visit fee that covers a one-year prescription and a 60-day consultation period. Auto-refill subscriptions can be paused or canceled before shipment at no cost. Musely advertises a 60-day money-back guarantee, but it generally does not apply to prescription hair treatments (which the company states are nonrefundable), so do not count on a refund for these products. Generic 5% minoxidil bought over the counter is far cheaper if you do not need the compounded combination.

Designed for adult men (typically 18+) with mild-to-moderate male-pattern hair loss, especially at the crown/vertex and frontal areas; earlier treatment generally protects more hair. It requires a telehealth medical evaluation before a clinician decides whether to prescribe it. Finasteride is not approved for and should not be used by women, and it must never be handled by anyone who is or may become pregnant because of the risk of birth defects in a male fetus. Avoid if you have a finasteride or minoxidil allergy; men planning to conceive, with a history of depression, or with liver or cardiovascular concerns should discuss the risks with a clinician first.

Intended for adults with hormonal or pattern hair loss (androgenetic alopecia), general thinning, telogen effluvium, or postpartum shedding, after a clinician approves the prescription. It is not for scarring or autoimmune hair loss (e.g., alopecia areata), which need a different medical evaluation. Women who are pregnant, trying to conceive, or breastfeeding must avoid dutasteride and spironolactone (risk of harm to a developing fetus, including feminization of a male fetus), and tretinoin is also contraindicated in pregnancy; women should not even handle the dutasteride-containing products in these situations. Men concerned about sexual or mood side effects, and anyone with a history of depression or suicidal thoughts, should weigh the DHT-blocker risks carefully with the prescriber. People with low blood pressure, heart conditions, or kidney problems should flag minoxidil and spironolactone use, and you should always confirm a diagnosis with a clinician before starting.